Institute of Dental Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague 121 11, Czech Republic.
Biomed Res Int. 2021 Jun 3;2021:5512091. doi: 10.1155/2021/5512091. eCollection 2021.
This study is aimed at proving the clinical benefit of the MELISA® test in the minimization or complete elimination of health problems in patients with confirmed hypersensitivity to metals used for tissue replacements. A group of 305 patients aged 20-75 years with previously proven metal hypersensitivity (initial MELISA® test), mainly to titanium and then to another fifteen metals, was chosen from the database at the Institute of Dental Medicine. From these patients, a final group of 42 patients agreed to participate in the study, 35 of which were female and 7 were male. The patients completed a special questionnaire aimed at information regarding change of health status from their last visit and determining whether the results of the initial MELISA® test and recommendations based on it were beneficial for patients or not. They were clinically examined, and peripheral blood samples were taken to perform follow-up MELISA® tests. Questionnaire data was processed, and the follow-up MELISA® test results were compared with the results of the initial MELISA® tests. For statistical analysis, the Fisher's exact test and paired -test were used. Thirty-two patients reported that they followed the recommendations based on the results of the initial MELISA® tests, and of these, 30 patients (94%) confirmed significant health improvement. Six patients did not follow the recommendation, and from these, only one patient reported an improvement in his health problems. By comparison of the initial and follow-up MELISA® test results, it can be stated that the hypersensitivity to the given metal decreased or disappeared after the therapeutic interventions performed based on the initial MELISA® test results. The evaluation of the data obtained from patients in this study confirmed a significant clinical benefit of MELISA® test.
本研究旨在证明 MELISA® 测试在减少或完全消除对用于组织替代的金属过敏患者的健康问题方面的临床益处。从牙科医学研究所的数据库中选择了一组 305 名年龄在 20-75 岁之间、先前已证实对金属过敏(初始 MELISA® 测试)的患者,主要是对钛,然后是另外十五种金属。从这些患者中,最终有 42 名患者同意参与研究,其中 35 名为女性,7 名为男性。患者填写了一份特殊的调查问卷,旨在了解他们上次就诊以来健康状况的变化,并确定初始 MELISA® 测试及其建议是否对患者有益。他们接受了临床检查,并采集外周血样进行后续 MELISA® 测试。对问卷数据进行了处理,并将后续 MELISA® 测试结果与初始 MELISA® 测试结果进行了比较。为了进行统计分析,使用了 Fisher 确切检验和配对检验。32 名患者报告说他们遵循了基于初始 MELISA® 测试结果的建议,其中 30 名患者(94%)确认健康状况显著改善。6 名患者没有遵循建议,其中只有 1 名患者报告其健康问题有所改善。通过比较初始和后续 MELISA® 测试结果,可以看出在基于初始 MELISA® 测试结果进行治疗干预后,对特定金属的过敏反应降低或消失。对本研究中患者获得的数据进行评估证实了 MELISA® 测试的显著临床益处。